rosoxacin
Also known as Roxadyl, ROS, Acrosoxacin, WIN-35213, Rosoxacine, Rosoxacino, Rosoxacinum
Rosoxacin (also known as acrosoxacin, tradename Eradacil) is a quinolone antibiotic indicated for the treatment of urinary tract infections and certain sexually transmitted diseases. Rosoxacin is not available in the United States.
Research
112 papers- Rosoxacin in the therapy of uncomplicated gonorrhea.Antimicrobial agents and chemotherapy · 1984
- Rosoxacin (Win 35,213) in the treatment of uncomplicated acute gonococcal infection.Clinical therapeutics · 1982
- Inhibition of IRAK1 Is an Effective Therapy for Autoimmune Hypophysitis in Mice.International journal of molecular sciences · 2022
- Rosoxacin and cinoxacin distribution in prostate, vagina, and female urethra. An experimental study in dogs.Investigative urology · 1979
- In-vitro antigonococcal activity of rosoxacin (WIN 35213).The British journal of venereal diseases · 1981
via PubMed
Article
3 sectionsContents
- Synthesis
- See also
- References
Rosoxacin (also known as acrosoxacin, tradename Eradacil) is a quinolone antibiotic indicated for the treatment of urinary tract infections and certain sexually transmitted diseases. Rosoxacin is not available in the United States.
It was developed in 1978 by George Lesher and his colleagues at Winthrop-Stearns (now part of sanofi-aventis), as an extension of the work that originally led to nalidixic acid.